The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries

Wu, Annie M.; Wu, Connie; Greenberg, Paul B.; Yu, Fei; Lum, Flora; Coleman, Anne L.

doi:10.1016/j.ajoc.2018.06.005

Cited by 3 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The possibility of endophthalmitis and retinal detachment following IVI of ranibizumab are of concern [ 7 , 20 ]. No such ocular adverse events occurred in our study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Narayanan

Kelkar²,

Abbas

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

Background Macular edema secondary to retinal vein occlusion (RVO) is an important cause of loss of vision. Intravitreal injections (IVI) of anti-vascular endothelial growth factor (VEGF) are the standard of care in this disease, as shown in numerous randomized controlled trials. The purpose of this study was to study the efficacy and safety of ranibizumab, an anti-VEGF agent, in the real-world setting. Methods This was 48 weeks, open-label, prospective, multicentre, observational study. Patients diagnosed with ME secondary to RVO were treated with IVI of Ranibizumab 0.5 mg in real-world conditions. Efficacy was measured by improvement seen in best-corrected visual acuity (BCVA) in terms of Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores and change in central retinal thickness (CRT) measured by optical coherence tomography. Results One hundred eyes of 100 patients (79 with branch retinal vein occlusion and 21 with central retinal vein occlusion) were recruited in the study. The mean (standard deviation, SD) BCVA was 52.8 (21.99) letters at baseline and 62.3 (24.40) letters at week 48. From baseline, there was a significant improvement in BCVA by 7.7 letters (p = 0.001) at 48 weeks. The mean (SD) of CRT was 479.9 (216.25) μm at baseline and it decreased significantly to 284.9 (171.35) μm at week 48 (p < 0.001). During the study period, the average number of intravitreal injections was 3.5 per patient. There was no report of endophthalmitis in any eye. Conclusions Ranibizumab is well tolerated and effective in treating macular edema secondary to RVO in real-world clinical settings. However, there is under-treatment compared to controlled clinical trials, and the gain in vision is sub-optimal with under-treatment. Trial registration Clinical Trials Registry - India: CTRI/2015/07/005985.

show abstract

“…The possibility of endophthalmitis and retinal detachment following IVI of ranibizumab are of concern [ 7 , 20 ]. No such ocular adverse events occurred in our study.…”

Section: Discussionmentioning

confidence: 99%

“…After the initiation of treatment with ranibizumab, BCVA was recorded at 4,8,12,16,20,24,28,36, and 48 weeks.…”

Section: Measurement Of Treatment Outcomesmentioning

confidence: 99%

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Narayanan

Kelkar²,

Abbas

et al. 2021

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States

Brown

Rapuano

et al. 2021

American Journal of Ophthalmology

View full text Add to dashboard Cite

<p>Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion</p>

Kumagai

Ogino²,

Fukami

et al. 2019

OPTH

View full text Add to dashboard Cite

Purpose The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO). Methods This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation. Results The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, P <0.0001) and at the final visit (all, P <0.0001). The differences in the BCVA between the three groups were not significant at all times after the initial treatment. Conclusion The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups.

show abstract

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries

Cited by 3 publications

References 16 publications

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab

A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States

<p>Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion</p>

Contact Info

Product

Resources

About